Aktienanalyse zu Tonix Pharmaceuticals Holding Corp (TNXP)TNXPTonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tonix Pharmaceuticals appears to be a good buy right now due to its current price of $5.15, significantly below its 52-week high of $20.56, indicating potential for recovery. The company has shown strong revenue growth, with Q2 2026 net product revenue reaching $13.54 million, up from $2 million year-over-year. Additionally, the gross margin has improved to 94.81% in Q2 2026, reflecting operational efficiency. However, the main risk is the high net loss of $40.6 million in Q2 2026, which could impact future performance if not managed effectively.

3 analysts cover TNXP: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 67.50.